Finch Therapeutics Group (FNCH) IPO Opens 20% Higher

Today's IPO for Finch Therapeutics Group, Inc. (NASDAQ: FNCH) opened for trading at $20.45 after pricing 7,500,000 shares of common stock at a public offering price of $17.00 per share.

BofA Securities, Jefferies and Evercore ISI are acting as joint book-running managers for the offering.

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.

You May Also Be Interested In

• BofA Securities Upgrades Ultrapar Holding (UGP) to Buy
• Freedom Metals Acquisition prices $275M IPO on Nasdaq
• South Korea's SK Hynix launches $28 billion US listing to ride global AI wave